Lymphangiogenesis: a new player in cancer progression.
Lymph node metastasis is the hallmark of colon cancer progression, and is considered one of the most important prognostic factors. Recently, there has been growing evidence that tumor lymphangiogenesis (formation of new lymphatic vessels) plays an important role in this process. Here, we review the latest findings of the role of lymphangiogenesis in colorectal cancer progression, and discuss its clinical application as a biomarker and target for new therapy. Understanding the molecular pathways that regulate lymphangiogenesis is mandatory to pave the way for the development of new therapies for cancer. In the future, tailored treatments consisting of combinations of chemotherapy, other targeted therapies, and anti-lymphangiogenesis agents will hopefully improve patient outcomes. This progression to the clinic must be guided by new avenues of research, such as the identification of biomarkers that predict response to treatment.
Nagahashi
Masayuki
M
Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and Massey Cancer Center, West Hospital,1200 East Broad Street, Richmond, VA 23298-0011, USA.
Ramachandran
Subramaniam
S
Rashid
Omar M
OM
Takabe
Kazuaki
K
D014408:Biomarkers, Tumor / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D018450:Disease Progression; D006801:Humans; D042583:Lymphangiogenesis / Q000502:physiology*; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic
D014408:Biomarkers, Tumor